SCHEMBL12434334

SCHEMBL12434334

Cc1ccc(CCC(=O)NCc2ccccc2-c2ccccc2C(=O)NCc2ccc(F)cc2F)cc1

nearest known ligand 0.68

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
KCNA5 P22460 4/20 0.68
KCNK3 O14649 2/20 0.68
KCNK5 O95279 1/20 0.68
KCNK17 Q96T54 1/20 0.68
KCNK9 Q9NPC2 1/20 0.68
ALDH1A1 P00352 2/20 0.47
LMNA P02545 3/20 0.42
TP53 P04637 1/20 0.42
P2RX7 Q99572 2/20 0.42
KMT2A Q03164 1/20 0.41
POLB P06746 1/20 0.41
RAB9A P51151 1/20 0.41
MAPT P10636 1/20 0.41
KCNH2 Q12809 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13789608 0.94 KCNA5 (0.62) KCNA5KCNK3KCNK5KCNK17KCNK9
SCHEMBL13789611 0.94 KCNA5 (0.59) KCNA5KCNK3KCNK5KCNK17KCNK9
SCHEMBL12434333 0.94 KCNA5 (0.69) KCNA5KCNK3KCNK5KCNK17KCNK9
SCHEMBL12434335 0.91 KCNA5 (0.66) KCNA5KCNK3KCNK5KCNK17KCNK9
SCHEMBL12434336 0.90 KCNA5 (0.84) KCNA5KCNK3KCNK5KCNK17KCNK9
SCHEMBL13789466 0.90 KCNA5 (0.57) KCNA5KCNK3KCNK5KCNK17KCNK9
SCHEMBL12434337 0.89 KCNA5 (0.66) KCNA5KCNK3KCNK5KCNK17KCNK9
SCHEMBL12434330 0.88 KCNA5 (0.65) KCNA5KCNK3KCNK5KCNK17KCNK9
SCHEMBL13789564 0.88 KCNA5 (0.57) KCNA5KCNK3KCNK5KCNK17KCNK9
SCHEMBL13789610 0.87 KCNK3 (0.71) KCNA5KCNK3KCNK5KCNK17KCNK9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7982045-B2 2′-substituted 1,1′-biphenyl-2-carboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2011-07-19 US disclosed
US-7982045-B2 2′-substituted 1,1′-biphenyl-2-carboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2011-07-19 US disclosed
US-20090192096-A1 2'-Substituted 1,1'-Biphenyl-2-Carboxamides, Processes For Their Preparation, Their Use As Medicaments, And Pharmaceutical Preparations Comprising Them SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2009-07-30 US disclosed
US-20090192096-A1 2'-Substituted 1,1'-Biphenyl-2-Carboxamides, Processes For Their Preparation, Their Use As Medicaments, And Pharmaceutical Preparations Comprising Them SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2009-07-30 US disclosed
US-7514582-B2 2′-substituted 1,1′-biphenyl-2-carboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2009-04-07 US disclosed
US-7514582-B2 2′-substituted 1,1′-biphenyl-2-carboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2009-04-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090192096-A1 2'-Substituted 1,1'-Biphenyl-2-Carboxamides, Processes For Their Preparation, Their Use As Medicaments, And Pharmaceutical Preparations Comprising Them MLLT3, RYR2, CACNA1E KCNA5 90/4885KCNK3 346/4885KCNK5 472/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.